04/04/2026
🧬 New Research Spotlight: Better Ways to Predict Outcomes in Common Variable Immunodeficiency (CVID) - A Study by Florida Allergists:
Common variable immunodeficiency (CVID) is one of the most frequent primary immunodeficiencies, marked by low antibody levels that lead to recurrent infections — and often serious non-infectious complications such as autoimmunity, organ damage, granulomatous disease, and increased cancer risk.
Until recently, it has been difficult for clinicians to reliably identify which patients face the highest risk of severe complications and reduced survival.
A large multicenter study published in The Journal of Allergy and Clinical Immunology (JACI) analyzed 209 CVID patients and provides valuable new insights through immunologic biomarkers:
Infectious complications (especially recurrent respiratory infections) were strongly linked to low serum immunoglobulins, particularly IgA.
Non-infectious complications (including splenomegaly, lymphadenopathy, interstitial lung disease, cytopenias, enteropathy, liver disease, and lymphoma) were more closely associated with specific cellular defects:
Late-onset combined immunodeficiency (LOCID), defined by severe reduction in naive CD4+ T cells.
Pronounced defects in classical CD27+ memory B cells (often with lower NK cells and IgM), linked to higher risk of enteropathy and liver disease.
Most importantly for prognosis:
Lower serum IgG, presence of LOCID, and especially the absence of CD27+ memory B cells were the strongest predictors of shorter survival.
Genetic risk alleles did not independently predict outcomes in this cohort.
These accessible biomarkers — measured through standard immunoglobulin levels and flow cytometry of T- and B-cell subsets — offer clinicians a practical way to stratify risk, intensify monitoring for high-risk patients, and personalize management strategies.
Early identification of those at greatest risk could meaningfully improve long-term outcomes and quality of life for people living with CVID.
Read the full study here: https://www.jacionline.org/article/S0091-6749(25)01079-6/fulltext
More than half of all symptomatic primary immunodeficiency patients receive a diagnosis of common variable immunodeficiency (CVID), with a prevalence in the general population of 1:25,000 to 1:50,000 individuals.1-3 CVID comprises a heterogeneous group of patients with unexplained decreased serum im...
